Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | Unknown unknown |
Therapy | Capivasertib + Paclitaxel |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | not applicable |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | triple-receptor negative breast cancer | not applicable | Capivasertib + Paclitaxel | Phase II | Actionable | In a Phase II trial (PAKT), addition of Capivasertib (AZD5363) to Taxol (paclitaxel) as first-line therapy resulted in improved median progression-free survival (5.9 vs 4.2 months, HR=0.74, p=0.06) and median overall survival (19.1 vs 12.6 months, HR=0.61, p=0.04) compared to Taxol (paclitaxel) alone in patients with metastatic triple-negative breast cancer (PMID: 31841354; NCT02423603). | 31841354 |
PubMed Id | Reference Title | Details |
---|---|---|
(31841354) | Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. | Full reference... |